Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain.
Red Española de Investigación en Patología Infecciosa (REIPI), Sevilla, Spain.
Eur J Clin Microbiol Infect Dis. 2018 Jan;37(1):51-56. doi: 10.1007/s10096-017-3100-y. Epub 2017 Sep 8.
The situations in which coverage for methicillin-resistant Staphylococcus aureus (MRSA) in the empirical treatment of nosocomial pneumonia (NP) or severe healthcare-associated pneumonia (HCAP) is needed are poorly defined, particularly outside intensive care units (ICUs). Our aim was to characterize if the risk of MRSA NP/HCAP can be defined by clinical variables. We designed an observational, retrospective, multicenter, case-control study to analyze the association between defined clinical variables and risk of MRSA NP/HCAP in non-ICU patients using conditional multivariable logistic regression. Cases and controls (1:2) with microbiological diagnosis were included. Controls were matched for hospital, type of pneumonia (NP or HCAP), and date of isolation. A total of 140 cases (77 NP and 63 HCAP) and 280 controls were studied. The variables associated with the risk of MRSA pneumonia were: (i) respiratory infection/colonization caused by MRSA in the previous year [odds ratio (OR) 14.81, 95% confidence interval (CI) 4.13-53.13, p < 0.001]; (ii) hospitalization in the previous 90 days (OR 2.41, 95% CI 1.21-4.81, p = 0.012); and (iii) age (OR 1.02, 95% CI 1.001-1.05, p = 0.040). The area under the receiver operating characteristic (ROC) curve for the multivariable model was 0.72 (95% CI 0.66-0.78). The multivariate model had a sensitivity of 74.5% (95% CI 65.3-83.6), a specificity of 63.3% (95% CI 56.0-70.6), a positive predictive value of 52.5% (95% CI 43.9-61.2), and a negative predictive value of 82.0% (95% CI 75.3-88.8) for the observed data. Clinical predictors of MRSA NP/HCAP can be used to define a low-risk population in whom coverage against MRSA may not be needed.
耐甲氧西林金黄色葡萄球菌(MRSA)在医院获得性肺炎(NP)或严重医疗保健相关性肺炎(HCAP)经验性治疗中的覆盖范围的情况定义很差,特别是在重症监护病房(ICU)之外。我们的目的是确定 MRSA NP/HCAP 的风险是否可以通过临床变量来定义。我们设计了一项观察性、回顾性、多中心、病例对照研究,使用条件多变量逻辑回归分析非 ICU 患者中定义的临床变量与 MRSA NP/HCAP 风险之间的关联。包括微生物学诊断的病例和对照(1:2)。对照与医院、肺炎类型(NP 或 HCAP)和分离日期相匹配。共纳入 140 例(77 例 NP 和 63 例 HCAP)和 280 例对照。与 MRSA 肺炎风险相关的变量包括:(i)MRSA 引起的呼吸道感染/定植在前一年[比值比(OR)14.81,95%置信区间(CI)4.13-53.13,p<0.001];(ii)90 天内住院(OR 2.41,95%CI 1.21-4.81,p=0.012);(iii)年龄(OR 1.02,95%CI 1.001-1.05,p=0.040)。多变量模型的接收者操作特征(ROC)曲线下面积为 0.72(95%CI 0.66-0.78)。多变量模型的敏感性为 74.5%(95%CI 65.3-83.6),特异性为 63.3%(95%CI 56.0-70.6),阳性预测值为 52.5%(95%CI 43.9-61.2),阴性预测值为 82.0%(95%CI 75.3-88.8)。临床预测因子可用于定义 MRSA NP/HCAP 的低危人群,在这些人群中可能不需要覆盖 MRSA。